Arcus Biosciences (RCUS) Q1 2025 Earnings
How Did RCUS Stock React to Q1 2025 Earnings?
S&P 500 over the same 30 days: +6.87%.
Did RCUS Beat Earnings? Q1 2025 Results
No. Arcus Biosciences reported Q1 2025 earnings of $-1.14 a share on May 6, 2025, missing the $-1.01 consensus estimate by 12.6%. Revenue was $28.0M against a $38.6M estimate.
Arcus Biosciences delivered a sharp miss on both the top and bottom lines in Q1 2025, as the clinical-stage oncology company absorbed the reversal of a landmark licensing windfall that had inflated year-ago comparisons. Revenue collapsed 80.7% year over year to $28.00 million, falling 27.47% below the $38.61 million consensus, as license and development services revenue plunged to $20.00 million from $135.00 million in Q1 2024 following the prior year's Gilead agreement milestone. The net loss widened dramatically to $112.00 million, or $1.14 per share, missing the $1.01 consensus estimate by 12.61%, with rising R&D expenses of $122.00 million reflecting accelerated Phase 2 enrollment across its pipeline. On the forward outlook, management guided for full-year 2025 GAAP revenue of $75.00 million to $90.00 million, a range that analysts have already received with skepticism, with recent estimates for the year revised meaningfully lower. The company's $1.00 billion cash position is expected to fund operations through pivotal readouts for its three lead programs, including the PEAK-1 Phase 3 trial in renal cell carcinoma, set to initiate in Q2 2025.
- Revenue decline driven by lower license and development services revenue from Gilead collaboration ($20M vs. $135M in Q1 2024)
- R&D expense increase of $13M driven by higher enrollment in Phase 2 studies and early-stage/preclinical activities
- G&A expense decrease driven by absence of one-time costs related to Third Gilead Agreement Amendment in Q1 2024
- February 2025 underwritten equity offering bolstered cash position
“Beginning with an oral presentation at ASCO for casdatifan in ccRCC, we expect to report a steady stream of data from ARC-20 throughout the remainder of 2025 and into 2026. We believe these data will support our robust development plan for casdatifan across multiple settings. This includes our Phase 3 trial, PEAK-1 in the IO-experienced setting, our clinical trial with AstraZeneca, which will combine casdatifan with their anti-PD-1/CTLA-4 bispecific antibody in the IO-naive setting, and three new cohorts in ARC-20 evaluating casdatifan in first- and second-line ccRCC.”
Arcus Biosciences CEO, on the earnings call
What Was Arcus Biosciences's Outlook in Q1 2025?
Arcus expects to recognize GAAP revenue of between $75 million and $90 million for the full year 2025. The company believes its $1.0 billion in cash, cash equivalents and marketable securities, together with available facilities, will be sufficient to fund operations through the initial pivotal readouts for domvanalimab, quemliclustat and casdatifan (including PEAK-1). The PEAK-1 Phase 3 trial is expected to initiate in Q2 2025, with PRISM-1 enrollment completion expected by end of 2025. Multiple data readouts are anticipated through the remainder of 2025 and into 2026.
RCUS YoY Financials
| Metric | Q1 2025 | Q1 2024 | Year over year |
|---|---|---|---|
| Revenue | $28.0M | $145.0M | −80.7% |
RCUS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.